POTE ankyrin domain family member DGenealiases: A26B3 · ANKRD21 · CT104.1 · POTE · POTE-21 · POTE21
Q-omics provides the consensus-scored POTED profile across patient tissues and cancer cell-line models. POTED expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, POTED is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, POTED RNA expression shows 6,342 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, BRCA, and TGCT as cancer lineages where POTED shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTED — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTED survival associations across molecular data types. POTED RNA expression shows survival associations in the most cancer types (10), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTED RNA expression–survival associations across cancer types. High POTED expression shows unfavorable associations in READ, PCPG, ACC, THYM and BLCA, but favorable associations in BRCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for POTED RNA expression.
This table summarizes POTED tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for POTED. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTED shows lower tumor expression in KIRC and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher POTED RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .020).
This table shows molecular features associated with POTED in patient tissues and cancer cell lines. In patient samples, POTED shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, POTED RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
